Skip to main navigation Skip to search Skip to main content

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis or Immunoglobulin A Nephropathy

Grants and Contracts Details

StatusActive
Effective start/end date7/1/21 → 1/29/27

Funding

  • Syneos Health LLC: $83,958.00